1, Anke Bio, the main business is the production and sale of biological products, proprietary Chinese medicines and chemical synthetic drugs. It is recognized by outsiders for its growth hormone business. But in fact, its business is wider and more complex, including biological drugs, proprietary Chinese medicines, chemical drugs, peptide drugs, genetic testing, cell therapy and so on. There are 7 wholly-owned subsidiaries and many participating holding companies, such as Anke Yu Liangqing, Anke Hengyi, Suhao Yiming, Zhongde Meilian, etc.
2. Its main products cover the fields of biologics, nucleic acid testing products, peptide drugs, modern proprietary Chinese medicines, chemical synthetic drugs, etc., and it has formed a series of precision medical whole industry chain layouts, such as genetic testing, targeted anti-tumor drug development, cellular immunotherapy technology, etc. The most core products include recombinant human interferon, which is the most important drug in the world for the growth hormone business. Our core products include recombinant human interferon, recombinant human growth hormone, blood-shedding cream, thymus pentapeptide and growth inhibitor.
Investment highlights
1. Fortune of the epidemic. Anke biological it interferon, thymus series and other products for the new crown pneumonia epidemic of important drugs. It is used as a recommended symptomatic treatment drug for new crown pneumonia. Recently, it developed two products, the new crown antibody detection kit and nucleic acid detection kit, which were recognized for export sales. As a result, it is gradually being tapped by the market funds, and the performance advance is expected, and therefore also recognized by the market funds.
2. Earned the money of the core. Anke biological core business is biological products, it is long-term commitment to cell engineering, genetic engineering, genetic testing, precision medicine and other biological and medical technology products, research and development, production and sales. Currently, bioproducts is the main core business. in 2019, its bioproducts contributed 75% of the company's net profit, 50.3% of its revenue, and 56.9% of its gross profit. In recent years, the net profit of biological products has also been showing an upward trend.
3. "Two Vegetables" are quite bullish. One is growth hormone, the other is interfering hormone. Anke Bio is the leading supplier of growth hormone powder needles in China, and its growth hormone sales, from 153 million yuan in 2014, grew to 653 million yuan in 2019, with a 5-year compound growth rate of 34%. Interferon is used in a variety of diseases such as viral diseases and hairy cell leukemia. Its interferon, which is widely used as an antiviral drug, is followed by interferon ointment, eye drops and other dosage forms, which can also open up new growth space.
4. "Two wings" layout accurate. One wing is Chinese and Western medicines, and the other is precision medicine. In addition to its core business, it also carries out large and small mergers and acquisitions to develop synergistically with Chinese and Western medicines and precision medicine as the two wings. It has successively acquired Soho Yiming, Sino-German Meilian, and participated in Boshengji and Hubei Sanqiqi Bio, etc., and laid out its business in various fields such as monoclonal antibody, cellular immunotherapy, gene sequencing, etc. It owns more than 30 invention patents and 5 non-patent technologies, and independently researches and develops more than 10 national new drugs, thus realizing the diversified development mode of "endogenous+externally extended".
5
5. "Two needles" become complementary. One is a powder needle and the other is a water needle. Anke's powder needle compared to similar products, no preservatives, and than the activity of up to 3.0, more approved indications, the powder needle market share first, the competitive advantage is obvious, and part of the powder needle patients, will be converted to the use of water needles, to seize some of the share of water needles. Since the listing of water needles, sales have been high, and the proportion has been expanding, from 2013 to 2019, the share of water needles has increased from 53.3% to 71.3%, and the future of water needles to replace powder needles is a long-term trend. Anke Bio's long-acting water needles have completed clinical research in 2019, and are currently in the stage of pending declaration of production, reported production in 2020, and are expected to be approved in 2021, when the full product line coverage will significantly enhance the competitive advantage.